Intelligence Feed event · Equity · 2026-08-31

    HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in China

    Question

    HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in China

    Direct answer

    HUTCHMED announced that the Phase III SANOVO trial evaluating ORPATHYS (savolitinib) combined with AstraZeneca's TAGRISSO (osimertinib) met its primary endpoint. The trial demonstrated a statistically significant progression-free survival benefit in first-line MET-overexpressing EGFR-mutated non-small cell lung cancer patients. The positive clinical readout supports supplementary regulatory submissions in China, potentially expanding the market for targeted combination therapies in lung cancer.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-31
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in China”, revision 1, evidence through 2026-08-31. https://marketontology.com/market-events/2026-08-31/hutchmed-and-astrazeneca-report-positive-phase-iii-sanovo-trial-in-china-82c502

    EQUITY
    HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in China
    HUTCHMED announced that the Phase III SANOVO trial evaluating ORPATHYS (savolitinib) combined with AstraZeneca's TAGRISSO (osimertinib) met its primary endpoint. The trial demonstrated a statistically significant progression-free survival benefit in first-line MET-overexpressing EGFR-mutated non-small cell lung cancer patients. The positive clinical readout supports supplementary regulatory submissions in China, potentially expanding the market for targeted combination therapies in lung cancer.
    HCMAZN
    Impact
    68
    AUG 31
    SIG
    92%
    HCMAZN
    HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in China
    HUTCHMED announced that the Phase III SANOVO trial evaluating ORPATHYS (savolitinib) combined with AstraZeneca's TAGRISSO (osimertinib) met its primary endpoint. The trial demonstrated a statistically significant progression-free survival benefit in first-line MET-overexpressing EGFR-mutated non-small cell lung cancer patients. The positive clinical readout supports supplementary regulatory submissions in China, potentially expanding the market for targeted combination therapies in lung cancer.
    → Statistically significant Phase III trial data advances regulatory approval pathways in China, expanding addressable oncology royalty and licensing revenue.
    Impact
    HUTCHMED announced that the Phase III SANOVO trial evaluating ORPATHYS (savolitinib) combined with AstraZeneca's TAGRISSO (osimertinib) met its primary endpoint. The trial demonstrated a statistically significant progression-free survival benefit in first-line MET-overexpressing EGFR-mutated non-small cell lung cancer patients. The positive clinical readout supports supplementary regulatory submissions in China, potentially expanding the market for targeted combination therapies in lung cancer.
    Affected
    HCMAZN
    Transmission
    Statistically significant Phase III trial data advances regulatory approval pathways in China, expanding addressable oncology royalty and licensing revenue.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMclinical pipeline milestone realization and commercial royalty accelerationUp1-5dPositive Phase III SANOVO data announced for savolitinib combination therapy.
    AZNexpanded label indications for TAGRISSO combination regimensUp1-4wTAGRISSO was co-evaluated in the successful Phase III SANOVO clinical trial.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed12.12 2026-08-31-1.73%+14.52%+16.75%

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month